SEEL logo

Seelos Therapeutics (SEEL) Cash From Financing

Annual CFF

$11.38 M
+$12.97 M+812.27%

December 31, 2023

Summary

Performance

1-Year Change

+812.27%

3-Year Change

-56.77%

5-Year Change

+111.55%

15-Year Change

+354.82%

SEEL Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

59.71%
SEEL annual cash flow from financing activities is higher than 59.71% of companies in Healthcare sector

High & Low

All-time High

$112.07 M
SEEL annual cash flow from financing activities is currently -89.85% below its historical high of $112.07 million

3-Year Low

-$1.60 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
SEEL previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
SEEL next annual earnings announcement has not yet been scheduled

OtherSEELcash flowmetrics:

Annual CFI

-
SEEL annual cash flow from investing activities value is unknown

Annual CFO

-$23.91 M
SEEL annual cash flow from operations is -$23.91 million

Annual FCF

-$23.91 M
SEEL annual free cash flow is -$23.91 million

Annual CAPEX

-
SEEL annual capital expenditures value is unknown

Quarterly CFF

$742.00 K
-$1.43 M-65.81%

June 30, 2024

Summary

Performance

3-Month Change

-65.81%

1-Year Change

-70.2%

3-Year Change

+139.3%

5-Year Change

-58.15%

SEEL Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

61.3%
SEEL quarterly cash flow from financing activities is higher than 61.3% of companies in Healthcare sector

High & Low

All-time High

$57.41 M
SEEL quarterly cash flow from financing activities is currently -98.71% below its historical high of $57.41 million

3-Year Low

-$2.31 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2024
SEEL previous earnings announcement was published on Jun 30, 2024

Next Quarterly Earnings Report Date

N/A
SEEL next earnings announcement has not yet been scheduled

OtherSEELcash flowmetrics:

Quarterly CFI

-
SEEL quarterly cash flow from investing activities value is unknown

Quarterly CFO

-$972.00 K
SEEL quarterly cash flow from operations is -$972.00 thousand

Quarterly FCF

-$972.00 K
SEEL quarterly free cash flow is -$972.00 thousand

Quarterly CAPEX

-
SEEL quarterly capital expenditures value is unknown

TTM CFF

$7.72 M
+$3.05 M+65.38%

June 30, 2024

Summary

Performance

3-Month Change

+65.38%

1-Year Change

+7.83%

3-Year Change

+583.72%

5-Year Change

-49.97%

SEEL TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

49.56%
SEEL TTM cash flow from financing activities is higher than 49.56% of companies in Healthcare sector

High & Low

All-time High

$112.07 M
SEEL TTM cash flow from financing activities is currently -93.11% below its historical high of $112.07 million

3-Year Low

-$1.60 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2024
SEEL previous earnings announcement was published on Jun 30, 2024

Next Quarterly Earnings Report Date

N/A
SEEL next earnings announcement has not yet been scheduled

OtherSEELcash flowmetrics:

TTM CFI

-
SEEL TTM cash flow from investing activities value is unknown

TTM CFO

-$13.27 M
SEEL TTM cash flow from operations is -$13.27 million

TTM FCF

-$13.27 M
SEEL TTM free cash flow is -$13.27 million

TTM CAPEX

-
SEEL TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

SEEL Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+812.3%-70.2%+7.8%
3 y3 years-56.8%+139.3%+583.7%
5 y5 years+111.5%-58.1%-50.0%

SEEL Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-89.8%+812.3%-96.3%+132.1%-93.1%+583.7%
5 y5-year-89.8%+812.3%-98.7%+132.1%-93.1%+583.7%
alltimeall time-89.8%+700.4%-98.7%+110.4%-93.1%+245.3%

Seelos Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2024
-
$742.00 K(-65.8%)
$7.72 M(+65.4%)
Mar 2024
-
$2.17 M(-6.6%)
$4.67 M(-58.9%)
Dec 2023
$11.38 M(-812.3%)
$2.32 M(-6.7%)
$11.38 M(+58.8%)
Sep 2023
-
$2.49 M(-207.7%)
$7.16 M(+43.1%)
Jun 2023
-
-$2.31 M(-126.1%)
$5.01 M(-30.4%)
Mar 2023
-
$8.87 M(-570.0%)
$7.19 M(-550.5%)
Dec 2022
-$1.60 M(-101.4%)
-$1.89 M(-665.3%)
-$1.60 M(-107.8%)
Sep 2022
-
$334.00 K(-365.1%)
$20.53 M(+0.9%)
Jun 2022
-
-$126.00 K(-251.8%)
$20.34 M(-73.9%)
Mar 2022
-
$83.00 K(-99.6%)
$77.87 M(-30.5%)
Dec 2021
$112.07 M(+325.9%)
$20.24 M(>+9900.0%)
$112.07 M(+9.1%)
Sep 2021
-
$143.00 K(-99.8%)
$102.76 M(-5.7%)
Jun 2021
-
$57.41 M(+67.5%)
$109.00 M(+110.7%)
Mar 2021
-
$34.28 M(+213.4%)
$51.74 M(+96.6%)
Dec 2020
$26.31 M(-10.9%)
$10.94 M(+71.4%)
$26.31 M(+70.4%)
Sep 2020
-
$6.38 M(+4240.1%)
$15.44 M(-12.1%)
Jun 2020
-
$147.00 K(-98.3%)
$17.56 M(-8.5%)
Mar 2020
-
$8.85 M(>+9900.0%)
$19.18 M(-35.0%)
Dec 2019
$29.52 M(+449.1%)
$64.00 K(-99.2%)
$29.52 M(-12.1%)
Sep 2019
-
$8.50 M(+379.2%)
$33.57 M(+52.8%)
Jun 2019
-
$1.77 M(-90.8%)
$21.97 M(-5.7%)
Mar 2019
-
$19.19 M(+366.7%)
$23.29 M(+333.2%)
Dec 2018
$5.38 M(+115.0%)
$4.11 M(-232.3%)
$5.38 M(+284.9%)
Sep 2018
-
-$3.11 M(-200.3%)
$1.40 M(-82.4%)
Jun 2018
-
$3.10 M(+143.0%)
$7.92 M(-27.3%)
Mar 2018
-
$1.27 M(+865.9%)
$10.90 M(+336.0%)
Dec 2017
$2.50 M(-77.3%)
$132.00 K(-96.1%)
$2.50 M(+62.0%)
Sep 2017
-
$3.42 M(-43.7%)
$1.54 M(-17.7%)
Jun 2017
-
$6.08 M(-185.3%)
$1.88 M(-135.3%)
Mar 2017
-
-$7.13 M(+764.1%)
-$5.32 M(-148.3%)
Dec 2016
$11.00 M(-28.8%)
-$825.00 K(-122.0%)
$11.00 M(-2.9%)
Sep 2016
-
$3.75 M(-436.5%)
$11.33 M(-9.9%)
Jun 2016
-
-$1.11 M(-112.1%)
$12.58 M(-7.5%)
Mar 2016
-
$9.19 M(-1953.0%)
$13.59 M(-12.0%)
Dec 2015
$15.45 M(+96.5%)
-$496.00 K(-109.9%)
$15.45 M(-24.4%)
Sep 2015
-
$5.00 M(-5148.5%)
$20.44 M(+11.8%)
Jun 2015
-
-$99.00 K(-100.9%)
$18.27 M(+5.4%)
Mar 2015
-
$11.05 M(+146.1%)
$17.33 M(+120.3%)
Dec 2014
$7.87 M(-52.7%)
$4.49 M(+58.4%)
$7.87 M(+132.4%)
Sep 2014
-
$2.83 M(-372.2%)
$3.38 M(+526.7%)
Jun 2014
-
-$1.04 M(-165.8%)
$540.00 K(-96.9%)
Mar 2014
-
$1.58 M(>+9900.0%)
$17.42 M(+4.8%)
Dec 2013
$16.63 M(-19.9%)
$8000.00(-180.0%)
$16.63 M(-6.8%)
Sep 2013
-
-$10.00 K(-100.1%)
$17.85 M(-0.1%)
Jun 2013
-
$15.84 M(+1902.8%)
$17.87 M(+783.2%)
Mar 2013
-
$791.00 K(-35.7%)
$2.02 M(-90.3%)
Dec 2012
$20.77 M(+170.9%)
$1.23 M(>+9900.0%)
$20.77 M(+4.0%)
Sep 2012
-
$4000.00(-300.0%)
$19.97 M(-11.3%)
Jun 2012
-
-$2000.00(-100.0%)
$22.52 M(-5.1%)
Mar 2012
-
$19.53 M(+4353.7%)
$23.73 M(+209.5%)
DateAnnualQuarterlyTTM
Dec 2011
$7.67 M(-52.1%)
$438.60 K(-82.8%)
$7.67 M(-53.9%)
Sep 2011
-
$2.55 M(+111.2%)
$16.64 M(+24.5%)
Jun 2011
-
$1.21 M(-65.2%)
$13.37 M(-15.7%)
Mar 2011
-
$3.47 M(-63.1%)
$15.86 M(-0.8%)
Dec 2010
$15.99 M(+2413.9%)
$9.41 M(-1407.0%)
$15.99 M(+120.1%)
Sep 2010
-
-$720.10 K(-119.5%)
$7.27 M(-9.0%)
Jun 2010
-
$3.69 M(+2.4%)
$7.99 M(+88.3%)
Mar 2010
-
$3.61 M(+425.5%)
$4.24 M(+566.8%)
Dec 2009
$636.10 K(-68.9%)
$686.10 K(>+9900.0%)
$636.10 K(-157.3%)
Sep 2009
-
$0.00(-100.0%)
-$1.11 M(-0.0%)
Jun 2009
-
-$50.00 K(<-9900.0%)
-$1.11 M(-155.4%)
Mar 2009
-
$0.00(-100.0%)
$2.00 M(-1.9%)
Dec 2008
$2.04 M(-207.9%)
-$1.06 M(>+9900.0%)
$2.04 M(-49.0%)
Sep 2008
-
-$500.00(-100.0%)
$4.01 M(-1.0%)
Jun 2008
-
$3.06 M(+7599.0%)
$4.05 M(-303.5%)
Mar 2008
-
$39.80 K(-95.6%)
-$1.99 M(+5.0%)
Dec 2007
-$1.89 M(-112.5%)
$902.70 K(+2128.9%)
-$1.89 M(-139.9%)
Sep 2007
-
$40.50 K(-101.4%)
$4.75 M(+1.8%)
Jun 2007
-
-$2.97 M(-2324.2%)
$4.67 M(-38.5%)
Mar 2007
-
$133.60 K(-98.2%)
$7.59 M(-50.0%)
Dec 2006
$15.18 M(+251.5%)
$7.55 M(<-9900.0%)
$15.18 M(+103.6%)
Sep 2006
-
-$42.40 K(-16.9%)
$7.45 M(-8.1%)
Jun 2006
-
-$51.00 K(-100.7%)
$8.11 M(-33.6%)
Mar 2006
-
$7.72 M(-4459.4%)
$12.22 M(+183.1%)
Dec 2005
$4.32 M(-68.0%)
-$177.20 K(-128.7%)
$4.32 M(-60.6%)
Sep 2005
-
$617.90 K(-84.8%)
$10.96 M(+8.5%)
Jun 2005
-
$4.06 M(-2343.5%)
$10.10 M(-25.3%)
Mar 2005
-
-$180.90 K(-102.8%)
$13.53 M(+0.3%)
Dec 2004
$13.49 M(-46.4%)
$6.47 M(-2806.2%)
$13.49 M(+2.2%)
Sep 2004
-
-$238.90 K(-103.2%)
$13.20 M(-44.4%)
Jun 2004
-
$7.49 M(-3546.3%)
$23.75 M(+2.5%)
Mar 2004
-
-$217.20 K(-103.5%)
$23.17 M(-8.0%)
Dec 2003
$25.19 M(+126.0%)
$6.17 M(-40.1%)
$25.19 M(+26.2%)
Sep 2003
-
$10.31 M(+49.3%)
$19.96 M(+96.0%)
Jun 2003
-
$6.90 M(+283.3%)
$10.18 M(-21.8%)
Mar 2003
-
$1.80 M(+90.7%)
$13.02 M(+16.8%)
Dec 2002
$11.15 M(+1113.6%)
$944.60 K(+77.6%)
$11.15 M(+9.6%)
Sep 2002
-
$532.00 K(-94.5%)
$10.17 M(+3.6%)
Jun 2002
-
$9.74 M(<-9900.0%)
$9.82 M(+7637.2%)
Mar 2002
-
-$69.30 K(+99.7%)
$126.90 K(-86.2%)
Dec 2001
$918.50 K(-97.7%)
-$34.70 K(-118.9%)
$918.40 K(-36.8%)
Sep 2001
-
$183.30 K(+285.1%)
$1.45 M(-94.4%)
Jun 2001
-
$47.60 K(-93.4%)
$26.18 M(-25.4%)
Mar 2001
-
$722.20 K(+44.4%)
$35.10 M(-13.2%)
Dec 2000
$40.42 M(+418.2%)
$500.00 K(-98.0%)
$40.42 M(+1.3%)
Sep 2000
-
$24.91 M(+177.7%)
$39.92 M(+165.9%)
Jun 2000
-
$8.97 M(+48.3%)
$15.01 M(+148.3%)
Mar 2000
-
$6.05 M
$6.05 M
Dec 1999
$7.80 M(+43.0%)
-
-
Dec 1998
$5.46 M(+16.0%)
-
-
Dec 1997
$4.70 M
-
-

FAQ

  • What is Seelos Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Seelos Therapeutics?
  • What is Seelos Therapeutics annual CFF year-on-year change?
  • What is Seelos Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Seelos Therapeutics?
  • What is Seelos Therapeutics quarterly CFF year-on-year change?
  • What is Seelos Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Seelos Therapeutics?
  • What is Seelos Therapeutics TTM CFF year-on-year change?

What is Seelos Therapeutics annual cash flow from financing activities?

The current annual CFF of SEEL is $11.38 M

What is the all time high annual CFF for Seelos Therapeutics?

Seelos Therapeutics all-time high annual cash flow from financing activities is $112.07 M

What is Seelos Therapeutics annual CFF year-on-year change?

Over the past year, SEEL annual cash flow from financing activities has changed by +$12.97 M (+812.27%)

What is Seelos Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of SEEL is $742.00 K

What is the all time high quarterly CFF for Seelos Therapeutics?

Seelos Therapeutics all-time high quarterly cash flow from financing activities is $57.41 M

What is Seelos Therapeutics quarterly CFF year-on-year change?

Over the past year, SEEL quarterly cash flow from financing activities has changed by -$1.75 M (-70.20%)

What is Seelos Therapeutics TTM cash flow from financing activities?

The current TTM CFF of SEEL is $7.72 M

What is the all time high TTM CFF for Seelos Therapeutics?

Seelos Therapeutics all-time high TTM cash flow from financing activities is $112.07 M

What is Seelos Therapeutics TTM CFF year-on-year change?

Over the past year, SEEL TTM cash flow from financing activities has changed by +$561.00 K (+7.83%)